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Escherichia coli ordinarily resides in the lower gastrointestinal tract in humans, but some
strains, known as Uropathogenic E. coli (UPEC), are also adapted to the relatively harsh
environment of the urinary tract. Infections of the urine, bladder and kidneys by UPEC
may lead to potentially fatal bloodstream infections. To survive this range of conditions,
UPEC strains must have broad and flexible metabolic capabilities and efficiently utilize
scarce essential nutrients. Whole-organism (or “omics”) methods have recently provided
significant advances in our understanding of the importance of metabolic adaptation in
the success of UPECs. Here we describe the nutritional and metabolic requirements for
UPEC infection in these environments, and focus on particular metabolic responses and
adaptations of UPEC that appear to be essential for survival in the urinary tract.
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INTRODUCTION
Urinary tract infections (UTIs) are one of the most common bacterial infections worldwide,
accounting for ∼150 million cases annually (Stamm and Norrby, 2001). This places a significant
financial burden on the health-care system, costing up to USD$6 billion on treatment and
management each year. UTIs can be community-acquired or health-care related, and occurs in both
men and women.Women are significantly more at risk with almost 50% of all women experiencing
a UTI at least once in their lifetime (Foxman, 2003; Brumbaugh et al., 2013).
UTIs are categorized as complicated or uncomplicated on the basis of the type and duration
of antimicrobial therapy given to the patient (Hooton, 2012; Flores-Mireles et al., 2015).
Uncomplicated UTIs typically affect children, women and the elderly who are otherwise healthy
and have no structural urinary tract abnormalities. These are differentiated into upper and lower
UTIs, most commonly pyelonephritis (kidney) and cystitis (bladder), respectively. Uncomplicated
UTIs rarely cause any serious damage, and can be naturally cleared by the host immune response
even without antibiotic therapy (Hooton, 2012). Complicated UTIs on the other hand require a
prolonged therapy and are associated with an increased risk of chronic and/or recurrent infection.
Complicated UTIs are associated with urinary tract abnormalities such as urinary obstruction
and retention, immunosuppression, previous antibiotic exposure, and renal failure. Together these
factors compromise the urinary tract and increase the risk of serious complications and treatment
failure (Lichtenberger and Hooton, 2008).
A range of pathogens have been implicated in UTIs, including Gram-positive and Gram-
negative bacteria such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Staphylococcus
saprophyticus, and Enterococcus faecalis. However, the disease is predominantly caused by
Uropathogenic E. coli (UPEC; Schulz, 2011; Flores-Mireles et al., 2015; Su et al., 2016b), which
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accounts for up to 75% of all cases (Foxman, 2002, 2003;Martinez
and Hultgren, 2002) and 95% of community-acquired cases
(Kucheria et al., 2005).
UPEC are a pathotype of extraintestinal pathogenic E. coli
(ExPEC) and originate from the intestinal microbiome. Within
the intestine, UPEC rarely cause any complications and exist
in a beneficial symbiotic relationship with intestinal microflora
(Wiles et al., 2008). However, UPEC have adapted the ability to
disseminate and colonize other host environments such as the
urinary tract and bloodstream. Virulence factors, such as toxins,
modify, and damage the host to promote infection (Flores-
Mireles et al., 2015). In addition, physiological factors that do
not directly damage the host but nevertheless are essential for
UPEC growth and survival in the urinary tract are now being
appreciated for their role in pathogenesis (Alteri and Mobley,
2012). The capacity of UPEC to utilize nutritionally-diverse
environments such as the intestines, urine, bladder, kidneys, and
bloodstream clearly plays a significant role in its pathogenesis
(Brown et al., 2008; Eisenreich et al., 2010); UPEC metabolism
is tightly regulated and highly responsive to nutrient availability,
allowing survival with a wide range of nutrients in competitive,
fluctuating environments.
This review will discuss the nutritional and metabolic
responses of UPEC as it moves from the intestine to the
harsh environment of the urinary tract, where virulent infection
starts. Nutrients available for UPEC growth in the intestine
and urinary tract have been compared in order to explore
these two environments as growth mediums for UPEC. Genetic
and metabolic responses that allow UPECs to survive in and
cause infection in the urinary tract are discussed in relation to
the nutrients available inside the urinary tract. As the role of
metabolism during UPEC infection is critical to advance our
understanding of pathogenesis, we reflect on the prospect of
UPEC metabolism as a potential drug target, to combat the
antibiotic resistance that has already developed against 70% of
the drugs currently being used clinically for UPEC-induced UTIs
(Foxman, 2002).
UPEC LIFESTYLE FROM INTESTINE TO
THE URINARY TRACT
The gastrointestinal tract is considered the primary reservoir
of UPEC in humans. For successful colonization in their main
habitat, the colon, E. coli first needs to survive passage through
the acidic conditions of the stomach, and upper intestine, and
then penetrate the viscous upper mucus layer of the colon
epithelium (Møller et al., 2003), survive other host defense
mechanisms (Bergstrom et al., 2012) and compete with other
strains and species of the complex intestinal surface microbiota
for acquisition and utilization of nutrients (Freter et al., 1983;
Rang et al., 1999; Miranda et al., 2004). Some E. coli cells remain
or are shed into the intestinal lumen and then excreted in feces.
UTIs are usually initiated when UPEC contaminate and
colonize the urethra and migrate into the bladder lumen. Most of
the characterized strains of UPEC invade the bladder epithelium
and undergo an intracellular infection cycle (Martinez et al., 2000;
Justice et al., 2004) and there is evidence that this occurs in most
human UTIs (Rosen et al., 2007). The infection cycle is a complex
pathway involving epithelial attachment, invasion of host cells,
and intracellular proliferation, leading to the eventual rupture
of the bladder epithelial cell, dissemination and reinfection of
surrounding epithelial cells (Justice et al., 2004, 2006a; Andersen
et al., 2012). Infections of the lower urinary tract have the
potential to progress to the kidneys and enter the bloodstream
causing potentially fatal urosepsis, as shown in Figure 1 (Flores-
Mireles et al., 2015).
Many studies have focused on virulence factors that play a role
in mediating UPEC colonization of the bladder, most notably the
initial attachment of bacterial adhesive structures to the luminal
surface of the bladder epithelium. This step of infection has
been quite well characterized and has been a focus of attention
in the development of therapies for UTIs (Langermann et al.,
2000; Asadi et al., 2014). UPEC surface fibers, in particular Type
1 pili and their tip adhesin (FimH), recognize mannosylated
glycoprotein receptors present on the host epithelium, mediating
UPEC binding (Jones et al., 1995; Martinez et al., 2000). UPEC
also express a variety of other proteins on their surface, which
facilitates bacterial attachment (see Mulvey, 2002). Once bound,
UPEC may become internalized via endocytosis (Mulvey et al.,
1998); activation of the host Rho-family proteins, such as RhoA,
Cdc42, and Rac1 result in the rearrangement of the host cell
membrane, engulfing the bacteria in endocytic vesicles (Martinez
et al., 2000; Martinez and Hultgren, 2002).
Within the intracellular environment, which offers a degree
of protection from innate immune responses, UPEC grow
as dense clusters of bacteria encased in a polysaccharide-
rich matrix (Anderson et al., 2003). These clusters, known as
intracellular bacterial communities (IBCs), have been observed
in the murine model and the human cell-culture model of
UTI, as well as shed into human urine (Anderson et al.,
2003; Justice et al., 2004; Rosen et al., 2007; Andersen et al.,
2012). As UPEC proliferate and the cluster develops to
overwhelm the host cell, subpopulations of differentiated bacteria
develop, including highly motile bacteria and extensive bacterial
filaments—cells that have continued growth with an arrest
of cell division (Justice et al., 2004, 2006b; Andersen et al.,
2012). The development of motile and filamentous bacteria
accompanies host cell rupture, and promotes dissemination,
adhesion and colonization of surrounding host surfaces, whilst
helping avoid consumption by the innate immune system
(Justice et al., 2006b; Andersen et al., 2012). UPEC filaments
have the potential to divide and reform to the regular rod-
shaped cells that are able to invade new host cells (Rosen
et al., 2007; Andersen et al., 2012). During these changes,
UPEC would experience rapid substantial changes in nutritional
status.
NUTRITIONAL ASPECTS OF THE
INTESTINE AND URINARY TRACT
ENVIRONMENTS FOR UPEC
UPEC must rapidly adapt to new environments as they
transition between the intestinal lumen and urinary tract, in
both intracellular and extracellular host microenvironments. In
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FIGURE 1 | UPEC pathogenesis across multiple microenvironments: Uropathogenic E. coli harmlessly grow in the human intestines as part of the microbiome. Within
this environment, UPEC interact with the intestinal epithelial cells in a symbiotic relationship, however there is competition for nutrients between other microorganisms.
UPEC has also adapted the ability to cause urinary tract infections and urosepsis by transitioning to a pathogenic lifecycle in the urinary tract and bloodstream. To gain
a stronghold within the urinary tract, UPEC express numerous pili systems to facilitate attachment to the superficial bladder epithelial cell layer. Invasion into the host
cell initiates replication immediately to form IBCs and a subpopulation undergoes cell elongation (filamentation). Eventually the epithelial cell is overloaded and UPEC
escape, rupturing open the host cell releasing motile short and elongated cells which can infect neighboring host epithelia to continue the infective cycle.
the urinary tract, urine is one of the major sources of nutrients
encountered by UPEC during the extracellular phase of the
infection cycle. Table 1 outlines the principle compounds that
demonstrate the potential to serve as sources of essential elements
within the intestine and urine that can support UPEC growth.
Intestine
Within the intestine, most UPEC strains are thought to exist like
other strains of commensal E. coli, as they do not directly cause
pathogenic infection there. The major source of nutrients utilized
by E. coli is provided by the mucus layer in which they live,
which contains surface-associated and secreted glycoproteins
(mucins) that are catabolized by the intestinal microbiota to
yield a variety of sugars, including N-acetylneuraminic acid
and N-acetylglucosamine that UPEC can utilize as a source of
carbon and energy (Severi et al., 2007; Katouli, 2010). Proteins,
lipids and nucleic acids present in the intestinal mucus layer,
including those originating from shed host epithelial cells and
exogenous dietary fiber may also be utilized as a nutrient source
(Conway et al., 2004). Degraded components of mucus and the
epithelium may also diffuse into the intestinal lumen, where they
can be utilized during UPEC metabolism within the intestine.
The competition for carbon sources, particularly sugars, in
the complex ecosystem of the colon is considered the main
nutritional limitation for E. coli in this environment (Conway
and Cohen, 2015). Consequently, E. coli have developed the
capacity to simultaneously metabolize numerous types of sugars,
and independently and rapidly regulate their production of the
enzymes required, in order to compete (Maltby et al., 2013).
Essential salts and metal ions are present in sufficient quantities,
however, some essential ions, particularly iron and zinc, may be
limiting and subject to intense competition (Gielda and DiRita,
2012; Kortman et al., 2014).
Urine
The urinary tract offers a very different and diverse set of
microenvironments that may be utilized by UPEC if the
numerous nutritional and immunological stresses encountered
here can be overcome. UPEC nutrition and metabolic responses
during the invasive intracellular infection phases are described
further below. Here, we outline the constituents of urine in
relation to UPEC nutrition, since survival or growth in urine is
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TABLE 1 | Potential sources of essential elements in two of the principal environments supporting UPEC growth, the upper mucus layer in the colon, and urine in the
urinary tract, with concentrations in indicated where known (C-carbon, O-oxygen, H-hydrogen, N-nitrogen, S-sulfur, P-phosphorus, K-potassium, Mg-magnesium,










Polysaccharides C, O, H Urea 22.5 ± 4.4 mM Bouatra et al., 2013 C, N, O, H
Dietary fibers C, O, H Creatinine 10.4 ± 2.0 mM Bouatra et al., 2013 C, N, O, H
Glycoproteins (N-acetylneuraminic
acid, N-acetylglucosamine)
C, N, O, H Hippuric acid 298.5 ± 276.8 µM Bouatra et al., 2013 C, N, O, H
Glycolipids C, O, H Organic acids: Citric acid 280.6 ± 115.2 µM Bouatra et al., 2013 C, O, H
Proteins C, N, O, H, S Amino acids: D-serine 3.0−40 µg/mL Cosloy and McFall, 1973;
Brückner et al., 1994;
Pätzold et al., 2005
C, N, O, H
Lipids C, O, H Nucleic acids – Bouatra et al., 2013 C, N, O, H, P
Nucleic acids C, N, O, H, P Oxytocin 0.9 ± 0.1 pM Bouatra et al., 2013 C, N, O, H, S
Phospholipids C, O, H, P Angiotensin II 1.2 ± 0.2 pM Bouatra et al., 2013 C, N, O, H
Ribose C, O, H Melatonin 3.3 ± 2.7 pM Bouatra et al., 2013 C, N, O, H
Fucose C, O, H Ammonia 2.8 ± 0.9 mM Bouatra et al., 2013 N, H
Mannose C, O, H Sodium 14.7 ± 9 mM Bouatra et al., 2013 Na
Gluconate C, O, H Chlorine 8.8 ± 6.2 mM Bouatra et al., 2013 Cl
Other dietary elements K, Mg, Ca, Fe Potassium 4.6 ± 0.1 mM Bouatra et al., 2013 K
*Concentrations in urine are normalized to creatinine concentration, considering a constant rate of creatinine excretion for each urine sample and to correct for dilution as different
volumes of urine samples were taken for analysis (Bouatra et al., 2013).
common to UPEC’s successful transition between the multiple
surface and sub-surface niches throughout the urinary system.
Understanding the complete metabolic profile of urine that
can be utilized by UPEC is challenging mainly due to urines
great compositional complexity and variability. Nonetheless,
advances in techniques such as metabolomics allow large-scale
simultaneous analysis of compounds in complex biological
mixtures and have greatly expanded knowledge of the metabolic
profile of urine (Patti et al., 2012).
The Human Urine Metabolome Database
All metabolites identified in pooled human urine to date
are available in a database termed the Urine Metabolome
Database (UMDB; Bouatra et al., 2013). Currently it contains
2,651 metabolites, with 220 metabolites specifically associated
with different conditions of disease. Although, the human
urine metabolome shows some similarity to the human serum
metabolome (Psychogios et al., 2011), there are more than 484
compounds uniquely identified in urine (Bouatra et al., 2013).
Whilst this indicates that there may be a subset of metabolites
that are unique to urine, it is likely that the composition of urine is
similar to blood, although certain metabolites from the blood are
most likely concentrated by the kidneys, resulting in them being
present at much higher concentrations compared to serum, and
thus above the detection levels for current metabolome analysis
(Bouatra et al., 2013).
Urine contains relatively high concentrations of urea,
creatinine, amino acids, organic acids, inorganic ions such as
ammonia, sodium and potassium, purines, pyrimidines, and
many water-soluble toxins, which must be either utilized or
tolerated by UPEC (Table 1; Vejborg et al., 2012; Bouatra et al.,
2013). In fact, urine contains 5–10 times more compounds
and exhibits 2–3 times more chemical diversity as compared
to other biological fluids like saliva (Takeda et al., 2009) and
cerebral spinal fluid (Mandal et al., 2012). The major metabolites
of urine are amino acids and carbohydrates. D-serine is the
most abundant amino acid in mammalian urine present at
concentrations between 30 and 379 µMol/L (Brückner et al.,
1994; Pätzold et al., 2005), whilst organic metabolites such as
hydroxyl acid, citric acid, ammonia, creatinine, and hippuric
acid are also present in significant quantities (Table 1). Despite
containing high concentrations of many metabolites that may be
utilized by UPEC, urine is classified as a fairly nutrient-limited
growth medium, because arginine, methionine, valine, uracil,
adenine and isoleucine are in limited supplies (Vejborg et al.,
2012), and iron is present in limited concentrations (Stamey and
Mihara, 1980), similar to many host environments harboring
bacteria. UPEC would largely rely on its capacity for de novo
synthesis of these and many other essential metabolites. The
least abundant metabolites available to UPEC in urine include
sugars, particularly glucose, specific peptides and hormones such
as oxytocin, angiotensin, and melatonin (Bouatra et al., 2013);
however despite being present in such low concentrations these
components do have the potential to fulfill the elementary
requirements of UPEC when catabolized. Thus, whilst urine
is perhaps nutritionally more challenging to support bacterial
growth compared to the intestinal environment, uropathogens,
including most UPEC strains, have well-developed metabolic
capacity to survive or thrive in this and other environments of
the urinary tract.
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GENETIC AND METABOLIC RESPONSES
IN UPEC PATHOGENESIS
The consequence of the metabolic diversity of urine on the
growth of UPEC within the urinary tract still remains to be
fully understood. Considering the different nutritional standings
of the intestine and urinary tract and the variability within
each, urinary metabolites are most likely to activate genetic
and metabolic adaptive strategies in UPEC in order to survive
and cause infection inside the urinary tract, some of which are
detailed here.
Central Carbon Metabolism
During intracellular UPEC colonization of the bladder
and kidneys, aerobic respiration and carbon metabolism
are essential for survival (Figure 2; Alteri et al., 2009).
UPEC pyelonephritis isolate CFT073 defective in sdhB, the
succinate dehydrogenase enzyme involved in the conversion
of fumarate to succinate during the tricarboxylic acid cycle,
is significantly outcompeted by the isogenic parental strain in
mouse bladder and kidney UTI models (Alteri et al., 2009).
Similarly, disruption of gluconeogenesis by deletion of pckA,
encoding for phosphoenolpyruvate carboxykinase which
catabolizes oxaloacetate to phosphoenol pyruvate, results in a
significant reduction in fitness to colonize both bladder and
kidneys in vivo when compared to wild-type (Alteri et al.,
2009). However, mutants defective in gluconate catabolism
of the Entner-Doudoroff pathway, by deletion of edd, do not
affect in vivo fitness in a mouse UTI model, suggesting this
pathway is dispensable in UPEC pathogenesis of UTIs (Alteri
et al., 2009), and indicates a specific metabolic adaptation by
UPEC during bladder infection that utilizes gluconeogenesis
and the tricarboxylic acid cycle. It should be noted that the
infection model used in this study only demonstrates the fitness
defect in the mutants of these enzymes as compared to wild
type and does not rule out the importance of other metabolic
adaptations during UPEC infection. Interestingly, in a kidney
mouse model of UTI, deletion of tpiA, the triosephosphate
isomerase involved in glycolysis, was found to have attenuation
and a colonization defect in the mouse kidneys, but not in the
bladder (Alteri et al., 2009). Thus, it appears that the glycolysis
pathway is dispensable during the initial establishment of
infection within the bladder, but is critical for colonization
of the kidneys. This evidence suggests that gluconeogenesis
and the tricarboxylic acid cycle must come to completion for
UPEC pathogenesis during intracellular infection of the bladder,
whilst glycolysis is important in kidney colonization during
UTIs.
β-galactosides and sorbitol appear to provide a major source
of carbon during intracellular infection in the urinary tract as
FIGURE 2 | Summarized view of the main metabolic responses of UPEC during urinary tract infection, as detailed in text under the section “Genetic and metabolic
responses in UPEC pathogenesis.” In comparison to the intestine, wherein glycolysis and Entner-Doudoroff pathways are shown to be important for UPEC survival,
UPEC in the urinary tract displays a number of metabolic adaptations in central carbon metabolism, amino catabolism and other pathways, to cause infection in the
urinary tract. Genes identified to play a role in UPEC pathogenesis are shown, having detailed information in text. Genes in blue color denote genes that play a role in
UPEC fitness in the urinary tract, or result in attenuation in a mouse or in vitro model of invasion and intracellular bacterial community formation. The gene in red
denotes a gene specifically identified to play a role in kidney infection. Transporters are shown in green boxes over the cell membrane. sdhB, succinate
dehydrogenase; pckA, phosphoenolpyruvate carboxykinase; tpiA, triosephosphate isomerase; srlA, sorbitol transporter; lacZ, β-galactosidase; galK, galactokinase;
dsdX, D-serine specific transporter; dsdA, D-serine deaminase; dppA, periplasmic dipeptide transport protein; oppA, periplasmic oligopeptide-binding protein; tonB,
ferric iron uptake mediator; pur, genes involved in purine synthesis.
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both the sorbitol transporter, encoded by srlA, and the galactoside
catabolism gene, lacZ (encoding β-galactosidase that cleaves the
glycosidic bond in galactosides to release galactose), were found
to be significantly upregulated during bladder cell colonization
(Conover et al., 2016). This is further supported by galK mutants
(the gene product being involved in conversion of galactose to
glucose) producing significantly smaller IBCs compared to the
wild-type in a mouse UTI model, with both mutants eventually
being out-competed after 2 weeks of intracellular infection
(Conover et al., 2016). Positive X-Gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside) staining of UPEC during the
IBC stage of a mouse UTI model also implies strong β-
galactosidase activity (Justice et al., 2006b). Together, evidence
suggests glucose availability within intracellular infection is
limiting and UPEC are adapted to utilize galactose and sorbitol
as their prime carbon sources. This is in accordance with urine
metabolome studies, which show that glucose is rarely abundant
in the urinary tract unless in a diabetic situation (Bouatra et al.,
2013; Mobley, 2016).
Whilst glycolysis appears to have a critical role in the
colonization of kidneys by UPEC, the importance of this
metabolic pathway is not restricted to this E. coli pathotype or
host environment. Both glycolysis and the Entner-Doudoroff
pathway are vital for the survival of commensal E. coli in
the mouse intestine as the deletion of pgi (phosphoglucose
isomerase) and edd (6-phosphogluconate dehydratase)
genes, having major roles within glycolysis and the Entner-
Doudoroff pathway respectively, each display attenuated
intestinal colonization in a competitive murine colonization
model (Sweeney et al., 1996; Chang et al., 2004). Conversely,
whilst gluconeogenesis and the tricarboxylic acid cycle are
dispensable during UPEC intestine colonization (Chang
et al., 2004), they are critical for UPEC survival during
bladder infection, demonstrating the metabolic flexibility of
UPEC to adapt to nutrient availability within diverse host
environments.
Amino Acid Catabolism
The ability of UPEC to exploit the high mixtures of amino
acids and complex small peptides present within human urine
has long been considered an adaptation to this environment.
The utilization of these resources by UPEC is supported by the
upregulation of genes involved in amino acid catabolism during
growth in human urine, such as dsdA (D-serine deaminase)
(Snyder et al., 2004), and microarray studies have demonstrated
the upregulation of arginine, serine and histidine transporters
in UPEC during urine growth when compared to Luria-
Bertani media (Conover et al., 2016). Both serine and arginine
auxotrophs do not exhibit any major fitness defects in a mouse
UTI model (Alteri et al., 2009), indicating that these amino
acids are effectively utilized from the growth milieu. Small
peptide uptake is also important for UPEC infection, as dppA
(periplasmic dipeptide transport protein) and oppA (periplasmic
oligopeptide-binding protein) deletion mutants defective in
peptide transport in CFT073, were significantly out-competed
by wild-type in the mouse bladder model of UTI (Alteri et al.,
2009). Interestingly, a subset of genes involved in amino acid
utilization and synthesis, most notably tryptophan and cysteine,
were downregulated during the IBC stage of infection (Conover
et al., 2016), and strains that are auxotropic for these amino
acids have the ability grow to a high density in urine (Hull and
Hull, 1997). This suggests that short peptide and selective amino
acid uptake and catabolism is necessary for growth in human
urine and correlates with the high concentrations of amino acids
reported in the metabolomic analysis of human urine (Table 1).
However, small peptides and amino acids must be available
from alternate sources apart from urine during the infection
cycle, as UPEC mutants auxotrophic in arginine, glutamine
and guanine synthesis have all shown a severe growth defect
in human urine, while leucine, methionine and phenylalanine
auxotrophs displayed a moderate growth rate (Hull and Hull,
1997).
A potential metabolic signaling mechanism evident in UPEC
during urine growth is that of the amino acid D-serine, present in
high concentration (3.0–40 µg/mL) in human urine (Cosloy and
McFall, 1973; Brückner et al., 1994; Pätzold et al., 2005). Whilst
potentially bacteriostatic at these concentrations, the expression
of D-serine deaminase in UPEC isolates allows for catabolism
of this metabolite (Roesch et al., 2003; Snyder et al., 2004).
Because of this, catabolism of D-serine was suggested to be a vital
signaling mechanism for virulence factor expression as deletion
of dsdA (encoding D-serine deaminase) displays a prolonged log
phase when grown in urine and a supposed hyper-colonization
phenotype in a competitive murine UTI model (Anfora et al.,
2007, 2008). Contrary to this, a subsequent study demonstrated
that the dsdA deletion does not lead to hyper-colonization
and that any gain of fitness phenotype previously reported is
likely due to an unrecognized secondary mutation in the sigma
factor rpoS gene (Hryckowian et al., 2015). RpoS associates
with the core RNA polymerase to control the expression of
∼10% of genes in E. coli, notably when under stressful nutrient-
limiting conditions (Weber et al., 2005). This suggests that the
unrecognized secondary mutation in rpoS may have affected
the dsdA mutant. Although D-serine may play a role as a
signaling mechanism for virulence factor expression, and UPEC
displays adaptive measures to allow growth in the presence of this
bacteriostatic metabolite, evidence suggests that D-serine does
not affect the capacity of UPEC to colonize the murine urinary
tract (Hryckowian et al., 2015).
Purines and Pyrimidines
UPEC can also adjust metabolic capacity to maintain growth
and colonization in the human bloodstream, subsequently
causing urosepsis in a small number of cases. The capacity
to defy the bactericidal activity of human serum and colonize
the bloodstream represents a crucial virulence advantage for
UPEC. It is possible that this virulence advantage could be due
to metabolic adaptation: mutagenesis studies identified genes
defective in both the de novo purine and pyrimidine nucleotide
biosynthetic pathway to be attenuated for commensal E. coli
growth in human serum after 24 h (Samant et al., 2008). This
study, making use of the Keio collection of mutants displayed
the greatest growth reduction in the purA, purE, pyrC, and
pyrE gene deletions when compared to growth in Luria-Bertani
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media (Samant et al., 2008). These defects were complimented
and restored when the appropriate nucleotide base precursor
was supplemented in the serum. This suggests that nucleotide
sugars and precursors are limiting for growth in human serum
forcing E. coli to undergo de novo biosynthesis to colonize.Whilst
this metabolic adaptation has not been demonstrated for UPEC
survival in serum directly, changes in the regulation of purine
and pyrimidine synthesis has been observed in the cystitis UTI89
strain (Hadjifrangiskou et al., 2011; discussed below). Thus,
the direct role of purine and pyrimidine synthesis for UPEC
metabolic adaptation for growth in serum remains an interesting
area to explore.
Iron Uptake and Transport Systems
UPEC express a variety of iron uptake and transport systems
such as iron-chelating siderophores and hemophores during
intracellular infection. Iron siderophores are low molecular
weight metal chelators involved in ferric iron scavenging
and play a major role in binding available iron to promote
UPEC intracellular colonization within the iron-limiting
urine and bladder epithelial cells. Transcriptome studies have
identified various genes involved in siderophore synthesis
to be dramatically upregulated during in vivo mouse UTI
infection, most notably salmochelin and yersiniabactin (Conover
et al., 2016). Further, greater production of yersiniabactin and
salmochelin in UPEC as opposed to commensal E. coli suggest
their possible role in facilitating infection of the urinary tract
by UPEC (Henderson et al., 2009). Interestingly, the ferric iron
uptake mediator TonB, which interacts with bacterial outer
membrane receptors to facilitate iron uptake, has shown to be
important in the mouse kidney model of UTI, with a deletion
of tonB resulting in a reduction in UPEC colonization at 48 h
post-infection when compared to wild type (Torres et al., 2001).
This highlights the necessity of iron uptake and transport
systems in UPEC pathogenesis.
The withholding of free iron by the host is usually mediated
by iron-binding proteins like lactoferrin, ferritin, transferrin,
ovalbumin and siderocalin (also known as lipocalin-2) (Miethke
and Marahiel, 2007). In an effort to counteract bacterial iron-
scavenging proteins, the host protein siderocalin, introduced
into the urinary tract by leukocytes and uroepithelial cells, can
restrict the accessibility of iron to UPEC by scavenging ferric
iron complexes (Goetz et al., 2002). Siderocalin shows very
high affinity to the bacterial siderophore enterobactin, which is
found ubiquitously in E. coli strains. However, the lower binding
affinity of siderocalin to other siderophores such as aerobactin,
salmochelin, and yersinibactin which are more often associated
with UPEC strains (Fischbach et al., 2006; Henderson et al.,
2009), may provide an evolutionary advantage for UPEC during
host iron scavenging. Indeed, purified siderocalin is capable of
effectively inhibiting E. coliK-12 that produces only enterobactin.
However, no effect was observed on the growth of E. coli that
produces all siderophores, such as UPEC (Garénaux et al., 2013).
The composition of human urine plays a role in the
regulation of siderocalin activity: an as-yet-unidentified urine
constituent inhibits the host siderocalin-mediated growth
restriction, allowing the bacterial siderophore enterobactin to
overcome the inhibitory iron-binding effects of siderocalin and
scavenge host iron (Shields-Cutler et al., 2015). Conversely, the
antibacterial activity of siderocalin was found to be associated
with urinary pH, with increasing pH shown to promote
siderocalin activity (Shields-Cutler et al., 2015). Other the other
side, acidic pH alone increases the solubility and availability of
iron partly contributing to the differences in iron availability
in solution and reducing the effect of siderocalin on bacterial
siderophores. Metabolomics studies identified the association of
increased urinary aryl sulfate metabolites, independent of the
urinary pH, with the antibacterial activity of siderocalin (Shields-
Cutler et al., 2015). The involvement of urinary constituents in
controlling the bacterial growth points to a urinary tract-specific
host-pathogen interaction system based on host metabolites and
bacterial siderophore biosynthesis during UTIs (Shields-Cutler
et al., 2015). This indicates that the host siderocalin uses urinary
metabolites as cofactors for restricting the availability of iron to
E. coli (Shields-Cutler et al., 2015) and that niche-specific roles
of siderophores drive their diversity among UPEC (Chaturvedi
et al., 2014; Shields-Cutler et al., 2015). Thus, whilst UPEC has
developed adaption strategies to utilize metabolites present in
host urine, these metabolites can also be utilized by the host as
a defense mechanism against UPEC infection.
Other Known Metabolic Regulators of
UPEC Pathogenesis
As well as the metabolic adaptation to survive and thrive within
the above environments, nutritional sensing is vital for UPEC to
efficiently respond to nutrient-fluctuating conditions within the
host environment, with several regulatory systems, as discussed
below, reported to be important for UPEC virulence.
RyhB
UPECnot only requires to upregulate the genes required for iron-
acquisition under iron-limited conditions of the urinary tract, but
also needs to precisely maintain the levels of iron required for
survival. The sRNA RyhB and the global ferric uptake regulator
Fur have been implicated for their role in iron acquisition and
controlling the storage of iron in E. coli (Massé and Gottesman,
2002). Fur and RyhB regulate the activity of cellular processes
such as metabolic pathways, with TCA cycle enzymes known
to be targeted by RyhB in E. coli (Massé et al., 2005). RyhB is
important for colonization of the urinary tract by UPEC strain
CFT073 via the production of iron-acquisition systems, with
a ∆ryhB mutant producing lower levels of the siderophores
aerobactin, salmochelin, and enterobactin (Porcheron et al.,
2014). Therefore, RyhB is shown to play a role in virulence of
the UPEC strain CFT073 (Porcheron et al., 2014).
BarA-UvrY
The two component system BarA-UvrY responds to nutritional
fluctuations through the action of regulatory RNAs CsrB and
CsrC and CsrA protein activity, which regulates expression
of genes involved in gluconeogenesis and glycolysis (Romeo,
1998; Suzuki et al., 2002; Weilbacher et al., 2003). Loss of
the response regulator UvrY results in decreased fitness in
both monkey cystitis and murine ascending UTI competition
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models (Tomenius et al., 2006; Palaniyandi et al., 2012), and
decreased invasion of uroepithelial cells (Palaniyandi et al., 2012).
Thus, the ability to effectively sense and utilize the mixture of
gluconeogenic and glycolytic carbon sources within urine is a key
metabolic adaption for UPEC survival.
QseBC
The two-component regulatory pathway system QseBC, consists
of QseC which functions as a sensory kinase to the environment
stimuli and host signal, resulting in phosphorylatation of the
transcription factor QseB, acting as the response regulator in
UPEC. This has been demonstrated by analyzing the qseC
mutant, which creates a positive feedback loop constantly
expressing QseB (Hadjifrangiskou et al., 2011). Furthermore,
deletion of qseC in the cystitis isolate UTI89 leads to attenuated
virulence and altered expression of 36 regulators, 52% of which
modulate at least 18 metabolic pathways (Hadjifrangiskou et al.,
2011). These include an increase in pyrimidine production and
utilization, whilst purine biosynthetic genes, purK, purM and
purT, as well as arginine synthesis genes, argF, argG, and argR
show downregulation (Hadjifrangiskou et al., 2011). Bypassing
purine production by the addition of guanosine or adenine
monophosphate was found to restore growth in a qseC mutant,
highlighting the importance of purine metabolism for UPEC
survival. This is interesting as de novo purine biosynthesis has
been recently shown to be essential for proliferation of UPEC
within the bladder during IBC, with ∆purF and ∆cupA-purF
operon displaying impaired fitness at 3, 6, and 16 h post-infection
in vivo (Shaffer et al., 2017).
fnr
Virulence gene expression also needs to be coordinated in
response to the availability of oxygen during oxygen-limiting
conditions within the bladder (Marteyn et al., 2010). Within
UPEC, the transcriptional regulator fnr controls oxygen-related
gene expression under anaerobic conditions. This regulator,
which contains a DNA-binding domain, was first identified when
the fnr mutant was no longer able to use fumarate and nitrate as
substrates during anaerobic growth (Lambden and Guest, 1976),
and also results in reduced metabolism of α-ketoglutarate under
oxygen-limited conditions (Barbieri et al., 2014).
Evidence suggests that, in addition to acting as an aerobic-
anaerobic metabolic regulator for UPEC, fnr controls virulence
gene expression within the bladder environment (Lambden and
Guest, 1976). The deletion of fnr within UPEC has shown a
decreased adherence and subsequently invasion capacity within
the epithelial cells of the kidneys and bladder when compared
to wild-type (Barbieri et al., 2014), due to multiple virulence
factor modifications such as a reduced expression of type 1 pili
and P fimbriae (Barbieri et al., 2014). In addition to this, the
fnr regulatory homolog within Salmonella has shown evidence
of positive virulence expression involved in cell flagella synthesis
and motility during pathogenesis (Contreras et al., 1997; Fink
et al., 2007). Therefore, fnr contributes to the pathogenesis of
UPEC by regulating the expression of important virulence genes
(Barbieri et al., 2014) in response to metabolism under different
aerobic conditions.
Pst
The loss of the phosphate-specific transport system (Pst),
encoded by the operon pstSCAB-phoU, results in the constitutive
activation of the Pho regulon, involved in phosphate transport
and metabolism. This constitutive activation has a negative effect
on UPEC pathogenicity, with a ∆pst CFT073 mutant displaying
a reduced fitness in a murine UTI model (Crépin et al., 2012).
This effect on virulence is thought to be due to the decreased
production of type 1 fimbriae in a ∆pst mutant, resulting in
decreased invasion of bladder epithelial cells (Crépin et al., 2012),
and demonstrates a link between nutrient sensing and UPEC
pathogenicity.
LINKING NICHE-SPECIFIC NUTRIENTS TO
THE ADAPTATION STRATEGIES OF UPEC
There is now mounting evidence that the metabolic flexibility
of the uropathogen UPEC is crucial for its ability to cause
infection of the urinary tract. This is due to the advancements
to understand the metabolome of human urine, resulting in
the creation of the human urine metabolome database, and
numerous studies that have detailed the effect of the loss of
a single metabolic enzyme on the fitness of UPEC during
urinary tract infection. Whilst this has provided valuable
information about the metabolic response of UPEC during
infection, understanding the complete metabolic requirements
of UPEC in the urinary tract is currently challenging due to
each metabolomics and genetic mutational studies being carried
out in isolation. Thus, major conclusions correlating the levels
of metabolites present in the host environment, and the role
of the corresponding bacterial metabolic pathway involved in
its catabolism are hard to draw. Ideally, whole-cell “omics”
approaches, including transcriptomics andmetabolomics, should
be carried out in concert with single gene deletion studies
to fully correlate the metabolic response with the virulence
of UPEC during infection. Using such approaches will also
minimize the variations due to sampling procedures, storage
conditions and environmental influences. For example, analyzing
the concentration of D-serine in urine, and correlating this to
the role of dsdA (encoding D-serine deaminase) in fitness during
UTI infection will allow us to further understand the direct
contribution that amino acid utilization plays during UPEC
metabolic adaptation.
New discoveries due to the advancement of “omics”
technologies such as metabolomics are also shaping our
understanding how UPEC interacts and adapts to nutritionally
distinct environments as it moves through the gastrointestinal
and urinary tracts. This data is imperative for the identification
of new disease biomarkers to improve the diagnosis of UTIs
(Mendrick and Schnackenberg, 2009) and for the discovery of
novel antibiotic drug targets (Wishart, 2016). However, despite
the potential power that metabolomics approaches have in
resolving differences pertinent to disease processes (Lv et al.,
2011), in comparison to other “omics” research (genomics and
proteomics), metabolomics still struggles to cover even a small
section of the entire metabolome, having identified <1% of the
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known human metabolome (Bouatra et al., 2013). Furthermore,
due to the complexity of interconnectivity of metabolic processes,
analysis of data obtained from metabolomics studies can prove
to be difficult to interpret. Regardless, of these shortcomings,
to date, metabolomics has successfully allowed comparison
between UPEC and commensal E. coli, providing novel targets
for virulence-based diagnosis (Su et al., 2016a). These virulence
factors can be targeted to control the UPEC pathogenic
mechanisms, thereby serving as potential drug targets (Hannan
et al., 2012; Kostakioti et al., 2012; Subashchandrabose et al., 2014;
Flores-Mireles et al., 2015; Yan et al., 2015; Su et al., 2016a,b).
METABOLISM AS A POTENTIAL
ANTIBACTERIAL TARGET FOR UTIS
Drug Targets
Most of the presently used antimicrobial drugs target a limited
number of bacterial processes, which are essential under
nutrient-rich conditions. However, growth in a nutrient-rich
medium in a laboratory setting does not reflect conditions within
the host, wherein UPEC must co-exist with gut microbes for
available nutrients, as well as display metabolic flexibility to adapt
to the harsh and comparatively nutrient-scarce urinary tract
environment. Under such circumstances, UPEC has developed
novel strategies through metabolic adaptations in order to adjust
and survive the challenging environment of the urinary tract.
New drugs to be developed must target adaptive strategies of
UPEC that are essential for survival in the host environment;
for example, the metabolic pathways shown to be important
for UPEC pathogenesis (Figure 2). Indeed, the longest standing
antibiotic class of sulfonamides target the metabolic process of
folate synthesis (Bourne, 2014), showing precedent for designing
drugs to target bacterial metabolism. Investigation of metabolic
pathways necessary for growth in a nutrient-restricted medium
serve as a better proxy for infection-causing conditions inside
the host, and has identified the essentiality of synthesis of amino
acids, nucleotides and vitamins (Côté et al., 2016); therefore such
processes are potential drug targets (Figure 3).
Under the nutrient stress conditions of the urinary tract,
genetic and metabolic adaptation studies of UPEC has shown
that central metabolic pathways are necessary for fitness of UPEC
in vivo, and amino acids and peptides serve as the main source
of carbon for UPEC during the urinary tract infection (Alteri
et al., 2009). These pathways therefore form a critical component
of the virulence of pathogenic microorganisms (Alteri et al.,
2009, 2015; Lv et al., 2011, 2014; Yan et al., 2015), and serve
as potential drug targets. For example, tpiA, which encodes
triosephosphate isomerase involved in glycolysis, is important for
kidney infection by UPEC (Alteri et al., 2009) and could therefore
be a potential drug target for the treatment of pyelonephritis.
Urine, being nutritionally restrictive, is unable to provide
all the growth factors required for bacterial growth, several of
which are synthesized de novo by bacteria that are adapted to
FIGURE 3 | Metabolism as a potential target for the development of new drugs and vaccines for UTIs, and the use of urine as a diagnostic fluid for UTI detection;
each with potential pros and cons associated with them. These potential targets are suggested by the authors as per the literature search.
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survival in this environment. Inhibitors of the synthesis process
of these growth factors may therefore have therapeutic value
for prophylaxis in the case of recurrent UTIs or for people
with high risk factors for infection (e.g., during pregnancy), as
well as treatment of uncomplicated UTIs (Hull and Hull, 1997).
For instance, biosynthetic pathways involved in the synthesis of
carbohydrates, purines and pyrimidines, and energy metabolism,
those involved in D-serine utilization (dsd locus) and uptake
of iron (tonB), are important factors contributing to bacterial
fitness in vivo. Antibiotics that target these metabolic pathways or
uptake systems hold the potential for treatment of UTIs (Vejborg
et al., 2012).
Vaccines
UTIs have a high recurrence rate of 25% (Bauckman and
Mysorekar, 2016) and can occur in an individual for the duration
of their lifetime, which requires long-term prophylaxis with
antimicrobials (Kodner and Thomas Gupton, 2010; Kostakioti
et al., 2012). Therefore, prevention using vaccines against
uropathogens would be a promising alternative, especially for
high-risk populations such as immunocompromised people and
pregnant women (Brumbaugh et al., 2013).
Iron-acquisition strategies of UPECs are of interest for the
development of novel diagnostics and therapeutics for UTIs
(Miethke and Marahiel, 2007). The continuous struggle for
iron between the host and the pathogen has spurred the iron-
related coevolution of host and the pathogen as a defense and
antidefense strategy by the two. This coevolution had resulted
in the development of siderophore-neutralization strategies by
the host in order to suppress the pathogen multiplication
and reutilization strategies by the pathogen. Additionally, hosts
have also developed cell conversion pathways and siderophore-
based iron delivery systems to break the pathogen’s supply of
iron. Successful treatment strategies could therefore focus on
weakening the iron-acquisition systems of UPECs or improving
the siderophore-neutralization strategies of the host.
This is an area of interest for vaccine development not just
restricted to UTIs, and has led to the development of vaccines
targeting some iron acquisition proteins; like yersiniabactin
uptake receptor FyuA, iron uptake aerobactin receptor IutA and
iron-responsive siderophore receptor IreA (Brumbaugh et al.,
2013), and siderophores yersiniabactin and aerobactin (Mike
et al., 2016). However, targeting a single iron receptor is unlikely
to yield a broad level of immunity because iron acquisition
mechanisms show functional redundancy in E. coli (Garcia
et al., 2011), and not all receptors are found in all UPEC
strains (Brumbaugh et al., 2013). Therefore, an iron receptor-
based multi-epitope vaccine against UPEC has the potential to
provide broad-spectrum immunization, as has been developed
for ExPEC, which has shown two-fold reduction in the bacterial
load in a mouse peritonitis model (Wieser et al., 2010). It
is possible that a similar multi-epitope vaccine would provide
protection against diverse UPEC strains.
Siderophore synthesis is identified to modulate the differential
metabolome of UPEC and non-UPEC strains, therefore the
genes involved in synthesis of these siderophores are candidate
targets for the development of drugs and vaccines against
UPECs (Su et al., 2016a). Siderophores, which are traditionally
considered an important virulence factor for UTI (Chaturvedi
et al., 2014), have been recently demonstrated to enhance the
virulence of UPEC partially by modulating their amino acid
metabolism (Su et al., 2016a). Recent evidence has shown that
the siderophores aerobactin and salmochelin present in UPEC
have a stronger modulatory effect than other siderophores on
amino acid metabolism (Su et al., 2016b). Therefore, siderophore
biosynthesis and its associated metabolic pathways may be novel
targets for therapeutics and virulence-based diagnoses.
Diagnosis
The metabolic profile of infected urine, as analyzed by
metabolomics, may reveal promising biomarkers to be used
for the diagnosis of UTIs. Several examples have already been
identified, including trimethylamine and acetic acid, which have
potential for incorporation on to a dip strip (Karlsen and Dong,
2015). Another example is creatinine, a breakdown product of
creatine, defined as a biomarker for the diagnosis of nephropathy
(Ariza-Heredia et al., 2014). Higher creatine concentrations are
observed in UPEC-grown urine in comparison to non-UPEC
strain, therefore it may be used as a biomarker for the diagnosis
of UPEC infection (Su et al., 2016a). Similarly, metabolites
related to purine and pyrimidine metabolism are upregulated in
UPECs as compared to non-UPECs, for example guanine and
hypoxanthine (Su et al., 2016a). These twometabolites are known
to be critical for the virulence of uropathogens (Vejborg et al.,
2012; Karlsen and Dong, 2015), therefore hypoxanthine has the
potential to be used as a biomarker for the diagnosis of UTIs.
However, these potential markers for determining UTIs are from
studies performed by culturing UPEC in urine obtained from
healthy individuals under in vitro conditions (Karlsen and Dong,
2015), or by comparing the profile of metabolites produced by
UPECs and non-UPECs under in vitro conditions (Su et al.,
2016a), which are settings that are in the absence of host immune
and cellular responses. The urinary composition of a healthy
individual is highly likely to be very metabolically different from
that of a UTI patient, partly due to the inflammatory response
of the host. Furthermore, much of the work to establish the
role of metabolism during UPEC infection has been performed
using various mouse models, which raises concerns about the
conservation of metabolic responses as compared to human
infection. These factors together raises questions on using these
identified metabolites as a means of determining UTIs. Thus,
future studies should focus on understanding the metabolomic
profile of urine from UPEC-infected individuals to provide
reliable data for the identification of biomarkers of UTIs in
response to the host immune response.
Pros and Cons of Using Metabolism as an
Antibacterial Target
A number of studies have explored the urine metabolome of
a healthy person and there are many examples comparing
metabolite levels in a healthy person to a diseased person, thereby
drawing conclusions about the role of specific metabolites in
progression of a disease (Alonso et al., 2016; Feng et al., 2016).
To our knowledge, none of the suggested metabolites from those
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studies have been standardized for use as a diagnostic marker
for UTIs or developed as a potential drug target. This is most
likely due to the complexity of metabolism itself, which makes
it hard to get reliable and reproducible data required for any
metabolite to be used as a disease marker, or any metabolic
enzyme to be used as a drug target. Urine metabolomics analysis
is usually done on pooled urine samples, as done in the
Human urine metabolome project (Bouatra et al., 2013). This
provides information about the metabolome of the combined
urine sample obtained from different individuals rather than
the urinary composition of one individual. Therefore, the levels
of metabolites obtained from such studies do not hold a true
potential to be standardized for the determination of UTIs.
Further complicating is the fact that the levels of metabolites
can vary merely due to different physiological conditions of a
person which is unrelated to disease status (discussed in the
next paragraph). Therefore, the parameters for threshold levels
of metabolites must be carefully considered before determining
their potential for UTI diagnosis.
Although there are a number of potential biomarkers
identified through individual studies, one very critical point to
consider before selecting such metabolites as a suitable UTI
biomarker is that the concentration of certain metabolite can
naturally vary by as much as seven-fold in different individuals,
depending on a number of factors like age, gender, health
status, diet and activity level (Saude et al., 2007; Bouatra
et al., 2013). Overall, dietary intake appears to be the most
influential factor on the concentrations of urinary metabolites,
with the type of diet dictating the metabolite concentration.
For example, mannitol, which is commonly present in foods
like carrots, apples, pineapples and asparagus, is commonly
found in human urine because of its poor absorption by the
body (Bouatra et al., 2013). Similarly, chocolate and meat
intake are known to increase the concentrations of polyphenol-
derived phenolic acids and 1-methylhistidine, respectively, in
the urine (Sjölin et al., 1987; Rios et al., 2003). Some gender-
related effects are shown to influence the level of creatinine,
a major component of the human urine and often used to
normalize metabolite concentrations of urine samples. Increased
intake of creatine or a protein-rich diet is also shown to
increase the urinary excretion of creatinine (Taylor et al., 1989).
In addition to dietary influence on the urine metabolome,
the levels of metabolites in urine vary with the physiological
status; for example, the levels of 3-hydroxybutyric acid increases
during fasting (Bouatra et al., 2013). Therefore, a careful
consideration of patient gender, diet and physiological status
is necessary before drawing conclusions about any potential
UTI diagnostic biomarker. Moreover, further studies need to
be conducted to investigate the contribution of each of these
factors to the urine metabolome. However, such studies would
require a significant amount of technical expertise, considering
the diversity of urinary metabolites and the range of factors
contributing toward the variation in levels of those metabolites.
In addition to exploring the contribution of such factors to
the urine metabolome, conditions will need to be standardized
for the collection of samples for examination. For example,
baseline concentrations of the biomarker may vary if the urine
sample is collected under fasting conditions as compared to
non-fasting conditions, which has implications in the diagnosis
of a UTI.
One important point to consider when developing drugs that
target the process of metabolism, or for that matter, for all drugs
that target essential bacterial processes, is the potential side effects
on the balance of the microbiome in the gut. Therefore, ideally,
the target to be selected for drug development should be specific
to UPEC and should have minimal effect on the gut microbiota.
Since the availability of iron to UPEC is limiting in the urinary
tract, the uptake of iron using tonB transporter is important for
UPEC virulence. Therefore, the iron transporters in UPEC are
potential drug targets. However, for this target to be practically
viable, further research needs to be done toward investigating the
role of iron transporters for intestinal survival of the members of
gut microbiome, as the potential drug will have consequences on
the gut microbiome as well.
Despite potential shortcomings with using metabolomics
as an antibacterial target, the essentiality of metabolism for
bacterial survival and the requirement of its adaptation inside
the urinary tract make it a promising target for UPEC treatment.
However, the current knowledge of the urine metabolome is
incomplete, but further advancements in techniques to fully
quantify metabolites and their levels in urine will aid our
understanding of the human urine metabolome. In concert,
studies are being continuously done to explore the role of
metabolic enzymes in UPEC adaptation inside the urinary tract
and new metabolic enzymes are being discovered. Identification
of these metabolic enzymes and the roles they play in UPEC
adaptation, along with correlating those adaptation strategies to
the levels of corresponding metabolites in both the bacterial cell
and human urine will allow us to better identify novel drug
targets aimed specifically at UPEC metabolism.
CONCLUSION
UTIs are one of the most prevalent bacterial infections, resulting
in billions of dollars of expenditure every year (Stamm and
Norrby, 2001). Of greater concern however is the increasing issue
of antibiotic resistance amongst pathogens causing UTIs (Flores-
Mireles et al., 2015). Metabolism is an essential bacterial process
and has been shown to be critical for UPEC adaptation to specific
host environments during infection, making it an ideal potential
treatment target. Further, identifying the metabolic adaptation
strategies of UPEC strains can help uncover an entirely new
area with prospective exploitation for the development of novel
antimicrobials to treat UTIs.
Our current understanding of the urine metabolome and
UPEC metabolic adaptation is incomplete, partially due to
technological shortcomings and the complexity and quantity
of metabolites produced by UPEC, especially in response to
interaction with the host environment. However, there have been
recent efforts to understand the contribution of metabolism to
UPEC virulence. From the current knowledge, limited availability
of iron in urine appears to be the growth-limiting factor for
UPEC growth in human urine; therefore UPEC systems involved
in the uptake and utilization of iron seem to be a very promising
target for novel drug development. The most abundant amino
acid known to be present in urine is D-serine, which has been
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shown to be important for the virulence of UPEC (Vejborg
et al., 2012). Therefore, the systems involved in catabolism of
this amino acid also can be potential drug targets. Further
advancements in “omics” techniques, along with a multi-omics
approach, will provide better understanding of the adaptation
strategies of UPECs and will guide us in future treatment
developments.
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